Scientists have developed a new “smart” cancer drug candidate designed to remain largely inactive in healthy tissues and become activated primarily inside cancer cells. The approach could potentially offer a more targeted alternative to conventional chemotherapy, which can also damage healthy cells and cause significant side effects.
Developed Through Indian Research Collaboration
The candidate, RK-251, was developed through collaborative research led by Dr. Asis Bala of the Institute of Advanced Study in Science and Technology (IASST), an autonomous institute under the Department of Science & Technology, Government of India, and Dr. K.P. Bhabak of the Indian Institute of Technology Guwahati.
Uses Cancer Cells’ High ROS Levels
The drug exploits a biological difference between cancerous and healthy cells. Cancer cells often contain elevated levels of reactive oxygen species (ROS). When RK-251 enters a cancer cell, these high ROS levels trigger the drug and release NBDHEX, a potent anticancer compound.
NBDHEX works by blocking target proteins that cancer cells rely on for survival and resistance to treatment, thereby helping to attack the tumour cells more selectively.
Promising Results in Triple-Negative Breast Cancer
In preclinical testing, RK-251 demonstrated strong activity against aggressive triple-negative breast cancer cells, while showing substantially less impact on healthy cells. These findings suggest that the ROS-activated approach could help improve the selectivity of cancer treatment.
Zebrafish Study Shows No Obvious Toxicity
Researchers also evaluated the candidate in zebrafish embryos (Danio rerio). The behavioural study showed no obvious signs of toxicity, while the drug displayed the expected fluorescence in the presence of ROS. This provided additional evidence supporting its further investigation.
More Research Needed Before Human Trials
Although the findings are promising, RK-251 remains a preclinical drug candidate. Further laboratory and animal studies will be required to establish its safety, effectiveness, dosage and potential for clinical use. Human trials would be needed before determining whether the technology can become a viable cancer treatment.
The research has been published in the ACS Journal of Medicinal Chemistry.
